Receptor-Independent Pathways Apoptosis through Receptor-Dependent and Renal Cell Carcinoma Tumors Induce T Cell
暂无分享,去创建一个
J. Finke | C. Tannenbaum | T. Das | G. Sa | P. Rayman | K. Biswas | R. Bukowski | E. Paszkiewicz-Kozik | D. Kudo | C. Hilston | L. Moltó | Gaurisankar Sa
[1] E. Marchioni,et al. Expression of Fas and Fas ligand in human testicular germ cell tumours. , 2009, International journal of andrology.
[2] J. Finke,et al. TNF-α Induction of GM2 Expression on Renal Cell Carcinomas Promotes T Cell Dysfunction1 , 2007, The Journal of Immunology.
[3] C. Ruiz-Ruiz,et al. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition. , 2007, Molecular immunology.
[4] L. Lacombe,et al. 879: PD-L1 (B7-H1) Expression by Urothelial Carcinoma of the Bladder and BCG-Induced Granulomata: Associations with Localized Stage Progression , 2007 .
[5] P. Krammer,et al. In vitro generated human memory‐like T cells are CD95 type II cells and resistant towards CD95‐mediated apoptosis , 2006, European journal of immunology.
[6] A. Novick,et al. GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction. , 2006, Cancer research.
[7] I. Derweesh,et al. Degradation of NF-κB in T Cells by Gangliosides Expressed on Renal Cell Carcinomas1 , 2004, The Journal of Immunology.
[8] J. Finke,et al. Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells. , 2003, Cancer research.
[9] Simon C Watkins,et al. Tumor-induced apoptosis of T cells: amplification by a mitochondrial cascade. , 2000, Cancer research.
[10] M. Hengartner. The biochemistry of apoptosis , 2000, Nature.
[11] P. Krammer,et al. CD95's deadly mission in the immune system , 2000, Nature.
[12] F. Marincola,et al. Melanoma vaccines: the paradox of T cell activation without clinical response , 2000, Cancer Chemotherapy and Pharmacology.
[13] S. Ju,et al. Bioactivities of Fas Ligand-Expressing Retroviral Particles1 , 2000, The Journal of Immunology.
[14] M. Lotze,et al. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] T. Whiteside,et al. Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. , 2000, Blood.
[16] K. Bhalla,et al. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. , 2000, Cancer research.
[17] J. Blenis,et al. FADD is required for multiple signaling events downstream of the receptor Fas. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[18] T. Whiteside,et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. , 1999, Cancer research.
[19] V. Fadok,et al. Polyamine Regulation of Plasma Membrane Phospholipid Flip-Flop during Apoptosis* , 1999, The Journal of Biological Chemistry.
[20] Y. Yamashita,et al. Relationship between Fas‐ligand expression on carcinoma cell and cytotoxic T‐lymphocyte response in lymphoepithelioma‐like cancer of the stomach , 1999, International journal of cancer.
[21] J. Finke,et al. Inhibition of NF-κB Activity in Human T Lymphocytes Induces Caspase-Dependent Apoptosis Without Detectable Activation of Caspase-1 and -3 , 1999, The Journal of Immunology.
[22] F. Salazar-Onfray. Interleukin-10: a cytokine used by tumors to escape immunosurveillance , 1999, Medical oncology.
[23] N. Bander,et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] J. Finke,et al. Where have all the T cells gone? Mechanisms of immune evasion by tumors. , 1999, Immunology today.
[25] S. Rosenberg,et al. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. , 1999, Journal of immunology.
[26] F. Shanahan,et al. Fas counter-attack–the best form of tumor defense? , 1999, Nature Medicine.
[27] R. Greil,et al. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model. , 1998, Leukemia & lymphoma.
[28] J. Blenis,et al. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade , 1998, Current Biology.
[29] C. Brady,et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. , 1998, Journal of immunology.
[30] T. Whiteside,et al. The role of Fas/FasL in immunosuppression induced by human tumors , 1998, Cancer Immunology, Immunotherapy.
[31] T. Whiteside,et al. Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. , 1998, The Journal of clinical investigation.
[32] M. Peter,et al. Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.
[33] Xiaodong Wang,et al. Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.
[34] F. Shanahan,et al. The Fas Counterattack: A Molecular Mechanism of Tumor Immune Privilege , 1997, Molecular medicine.
[35] Erwin G. Van Meir,et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? , 1997, The Journal of clinical investigation.
[36] S. Nagata,et al. Apoptosis by Death Factor , 1997, Cell.
[37] S. Nagata. Fas ligand and immune evasion , 1996, Nature Medicine.
[38] F. Shanahan,et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.
[39] Xiaodong Wang,et al. Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.
[40] Arul M. Chinnaiyan,et al. FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis , 1995, Cell.
[41] G. Kroemer,et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo , 1995, The Journal of experimental medicine.
[42] S. Ju,et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.
[43] N. Bander,et al. Establishment and characterization of human renal cancer and normal kidney cell lines. , 1990, Cancer research.
[44] J. Nikliński,et al. Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus. , 2007, Folia histochemica et cytobiologica.
[45] L. Devgan,et al. Antisense TGF-β2 Immunotherapy for Hepatocellular Carcinoma: Treatment in a Rat Tumor Model , 2001, Annals of Surgical Oncology.
[46] J. Zeuthen,et al. Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient , 2001, Cancer Immunology, Immunotherapy.
[47] H. Kitagawa,et al. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape. , 2001, International journal of oncology.
[48] A. Novick,et al. Molecular Mechanisms of Immune Dysfunction in Renal Cell Carcinoma , 2000 .
[49] M. Peter,et al. Differences between CD95 type I and II cells detected with the CD95 ligand. , 1999, Cell death and differentiation.
[50] Z. Darżynkiewicz,et al. Features of apoptotic cells measured by flow cytometry. , 1992, Cytometry.